Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink

References

• Lomas J. Improving research dissemination and uptake in the health sector: beyond the sound of one hand clapping. Hamilton, 1997
   Google Scholar
• Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65
   PubMed Web of Science ®Google Scholar
• Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-16
   PubMed Web of Science ®Google Scholar
• Lomas J, Anderson GM, Domnick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321:1306-11
   PubMed Web of Science ®Google Scholar
• Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam Pract 2003;20:61-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health Care Excellence (Guideline 87). NICE Short Clinical Guideline 87 – Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. 2009. Available at: https://www.nice.org.uk/guidance/cg87
   Google Scholar
• NICE Technology Appraisal Guidance No. 203. Liraglutide for the Treatment of Type 2 Diabetes Mellitus. 2012. Available at: https://www.nice.org.uk/guidance/ta203
   Google Scholar
• NICE Technology Appraisals [TA248]. Exenatide Prolonged-Release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes. 2012. Available at: https://www.nice.org.uk/guidance/ta248
   Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52:751-9
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Preface and Amendments to the Drug Tariff – June 2013. Available at: http://www.ppa.org.uk/edt/December%202013.pdf [Last accessed 9 July 2013]
   Google Scholar
• Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read Codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996:75-9
   PubMedGoogle Scholar
• Campbell J, Dedman DJ, Eaton S, et al. Is the GPRD GOLD population comparable to the UK population? Pharmacoepidemiol Drug Saf 2013;22(Suppl 1):280
   Web of Science ®Google Scholar
• Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25
   PubMed Web of Science ®Google Scholar
• Ntuk UE, Gill JM, Mackay DF, et al. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care 2014;37:2500-7
   PubMed Web of Science ®Google Scholar
• Thong KY, Gupta PS, Cull ML, et al. GLP-1 receptor agonists in type 2 diabetes – NICE guidelines versus clinical practice. Br J Diabetes Vasc Dis 2014;14:52-9
   Google Scholar
• Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26:837-46
   PubMed Web of Science ®Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82
   PubMed Web of Science ®Google Scholar
• Heymann A, Maor Y, Goldstein I, et al. Efficacy of liraglutide in a real-life cohort. Diabetes Ther 2014;5:193-206
   PubMedGoogle Scholar
• Driskell OJ, Holland D, Hanna FW, et al. Inappropriate requesting of glycated hemoglobin (Hb A1c) is widespread: assessment of prevalence, impact of national guidance, and practice-to-practice variability. Clin Chem 2012;58:906-15
   PubMed Web of Science ®Google Scholar
• Hall GC, McMahon AD, Dain MP, et al. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med 2013;30:681-27
   PubMed Web of Science ®Google Scholar
• Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther 2013;4:27-40
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Forbes HJ, Douglas I, et al. Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open 2013;3:e003389
   Web of Science ®Google Scholar
• Wessels L, Keigan S, O’Brien SV, Hardy KJ. What proportion of patients fail NICE criteria for continuing GLP-1 treatment beyond six months, and why? Practical Diabetes 2013;30:196-8
   Google Scholar